Smith & Nephew (SNN) announced it has signed a distribution agreement with SI-Bone (SIBN), focused on their innovative iFuse TORQ portfolio. This collaboration expands the Smith & Nephew portfolio offerings for percutaneous pelvic fracture fixation procedures and strengthens its position in high-frequency, high-impact trauma procedures. “We’re incredibly excited to partner with SI-BONE,” said Scott Gunn, VP Trauma, Extremities and Shoulder. “This collaboration reflects a shared commitment to innovation, clinical excellence, and improving patient outcomes. By combining SI-BONE’s industry leadership with Smith+Nephew’s established commercial platform, we see a meaningful opportunity to expand access to differentiated solutions, deepen surgeon engagement, and drive sustainable growth.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNN:
- Smith+Nephew Sets 2 March 2026 Date for 2025 Full-Year Results
- Smith & Nephew Reports Routine Six-Month Update on Employee Share Schemes
- Smith & Nephew Updates Share Capital and Voting Rights as of 31 January 2026
- Smith & Nephew: Underappreciated Sports Medicine Growth Platforms Support Re‑Rating Potential and Justify Buy Rating
- Smith & Nephew Executives Buy ADS under Employee Stock Purchase Plan
